Abstract
Background: Cisplatin, a platinum-based chemotherapy agent, is used in the effective treatment of a wide range of malignant cancers. Resveratrol, a polyphenolic plant-derived compound, has been shown to have several biological effects including protecting the body against several forms of damages. Objective: This study assessed the effects of cisplatin and supplementation with resveratrol on some hematological parameters in Sprague-Dawley rats. Material and Methods: Forty-five adult female Sprague–Dawley rats, grouped into 9, were used for this experimental study. Group 1 served as the control group and received distilled water only. Groups 2 and 9 received Cisplatin only while groups 3, 4, and 5 received different doses of Resveratrol after a single dose of Cisplatin. Groups 6, 7, and 8 received Resveratrol before Cisplatin. Results: At the end of administration, blood samples were collected and different hematological parameters were accessed. Groups 2 and 5 showed a significantly higher Total WBC when compared to the control group (p<0.05). Group 7 showed a significantly higher (p<0.05) neutrophil count compared to both the control group and group 2, but a significant decrease in the lymphocyte count compared to the same groups (p<0.05). Groups 6 and 7 showed a significant reduction in monocyte when compared to the control group (p<0.05). There was no significant difference in the eosinophil count of all treatment groups when compared to the control group and cisplatin groups (p<0.05). Basophil increased significantly in group 7 when compared to the control group and group 2 (p<0.05). More so, a significant decrease in the Haemoglobin (Hb), Packed cell volume (PCV) and Mean corpuscular volume (MCV) level were observed when compared to group 9 (p<0.05). Conclusion: This study showed that cisplatin-induced alteration in some hematological parameters is reversible by treatment with resveratrol. More so, resveratrol supplementation should be incorporated as part of dietary nutrients for patients on cisplatin during chemotherapy.
Highlights
Cisplatin is an effective chemotherapeutic agent, which belongs in the platinum-based anti-neoplastic family of medications [1]
On examination of the hematological parameters in this present study, we found no significant change between groups in the red blood cell, eosinophils and mean corpuscular haemoglobin concentration (MCHC) (p>0.05)
Unlike Juan and co-workers in 2002 who found out that high-dose resveratrol administration did not change hematological parameters in rats, this present study found white blood cell (WBC) count to be significantly lower in the group that received high dose of resveratrol, as compared to the control group
Summary
Cisplatin is an effective chemotherapeutic agent, which belongs in the platinum-based anti-neoplastic family of medications [1] It is used in the treatment of a wide range of malignant diseases including testicular cancer, ovarian cancer, cervical cancer, breast cancer, bladder cancer, head and neck cancer, esophageal cancer, lung cancer, mesothelioma, brain tumors and neuroblastoma. Previous works by Wood and Hrusheeky in 1995 [3] showed, that cisplatin causes significant effects on various hematological parameters only during chronic treatment in humans and rats. Objective: This study assessed the effects of cisplatin and supplementation with resveratrol on some hematological parameters in Sprague-Dawley rats. There was no significant difference in the eosinophil count of all treatment groups when compared to the control group and cisplatin groups (p
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
